Pharmacological Co-Activation of TrkB and TrkC Receptor Signaling Ameliorates Striatal Neuropathology and Motor Deficits in Mouse Models of Huntington’s Disease
Restricted accessResearch articleFirst published online October 3, 2023
Pharmacological Co-Activation of TrkB and TrkC Receptor Signaling Ameliorates Striatal Neuropathology and Motor Deficits in Mouse Models of Huntington’s Disease
Loss of neurotrophic support in the striatum, particularly reduced brain-derived neurotrophic factor (BDNF) levels, contributes importantly to Huntington’s disease (HD) pathogenesis. Another neurotrophin (NT), NT-3, is reduced in the cortex of HD patients; however, its role in HD is unknown. BDNF and NT-3 bind with high affinity to the tropomyosin receptor-kinases (Trk) B and TrkC, respectively. Targeting TrkB/TrkC may be an effective HD therapeutic strategy, as multiple links exist between their signaling pathways and HD degenerative mechanisms. We developed a small molecule ligand, LM22B-10, that activates TrkB and TrkC to promote cell survival.
Objective:
This study aimed to determine if upregulating TrkB/TrkC signaling with LM22B-10 would alleviate the HD phenotype in R6/2 and Q140 mice.
Methods:
LM22B-10 was delivered by concomitant intranasal-intraperitoneal routes to R6/2 and Q140 mice and then motor performance and striatal pathology were evaluated.
Results:
NT-3 levels, TrkB/TrkC phosphorylation, and AKT signaling were reduced in the R6/2 striatum; LM22B-10 counteracted these deficits. LM22B-10 also reduced intranuclear huntingtin aggregates, dendritic spine loss, microglial activation, and degeneration of dopamine- and cyclic AMP-regulated phosphoprotein with a molecular weight of 32 kDa (DARPP-32) and parvalbumin-containing neurons in the R6/2 and/or Q140 striatum. Moreover, both HD mouse models showed improved motor performance after LM22B-10 treatment.
Conclusions:
These results reveal an NT-3/TrkC signaling deficiency in the striatum of R6/2 mice, support the idea that targeting TrkB/TrkC alleviates HD-related neurodegeneration and motor dysfunction, and suggest a novel, disease-modifying, multi-target strategy for treating HD.
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell. 1993;72(6):971–83.
3.
TabriziSJ, FlowerMD, RossCA, WildEJ. Huntington disease: New insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020;16(10):529–46. doi: 10.1038/s41582-020-0389-4.
4.
ReichardtLF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci. 2006;361(1473):1545–64. doi: 10.1098/rstb.2006.1894.
5.
SimmonsDA. Modulating neurotrophin receptor signaling as a therapeutic strategy for Huntington’s disease. J Huntingtons Dis. 2017;6(4):303–25. doi: 10.3233/JHD-170275.
6.
HuangEJ, ReichardtLF. Neurotrophins: Roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736. doi: 10.1146/annurev.neuro.24.1.67724/1/677.
7.
NakataniT, UenoS, MoriN, MatsuokaI. Role of NRSF/REST in the molecular mechanisms regulating neural-specific expression of trkC/neurotrophin-3 receptor gene. Brain Res Mol Brain Res. 2005;135(1-2):249–59. doi: 10.1016/j.molbrainres.2004.12.019.
8.
ZuccatoC, CattaneoE. Role of brain-derived neurotrophic factor in Huntington’s disease. Prog Neurobiol. 2007;81(5-6):294–330.
9.
ZuccatoC, TartariM, CrottiA, GoffredoD, ValenzaM, ContiL, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003;35:76–83.
10.
GauthierLR, CharrinBC, Borrell-PagesM, DompierreJP, RangoneH, CordelieresFP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004;118(1):127–38.
11.
LiotG, ZalaD, PlaP, MottetG, PielM, SaudouF. Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J Neurosci. 2013;33(15):6298–309. doi: 10.1523/JNEUROSCI.2033-12.2013.
12.
ZuccatoC, CiammolaA, RigamontiD, LeavittB, GoffredoD, ContiL, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science. 2001;293(5529):493–8.
13.
GinesS, BoschM, MarcoS, GavaldaN, Diaz-HernandezM, LucasJJ, et al. Reduced expression of the TrkB receptor in Huntington’s disease mouse models and in human brain. Eur J Neurosci. 2006;23(3):649–58.
14.
ZuccatoC, MarulloM, ConfortiP, MacDonaldME, TartariM, CattaneoE. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington’s disease. Brain Pathol. 2008;18(2):225–38. doi: 10.1111/j.1750-3639.2007.00111.x.
15.
BritoV, PuigdellivolM, GiraltA, DelToro D, AlberchJ, GinesS. Imbalance of p75(NTR)/TrkB protein expression in Huntington’s disease: Implication for neuroprotective therapies. Cell Death Dis. 2013;4:e595. doi: 10.1038/cddis.2013.116.
16.
MaloneyMT, WangW, BhowmickS, MillanI, KapurM, HerreraN, et al. Failure to thrive: Impaired BDNF transport along the cortical-striatal axis in mouse Q140 neurons of Huntington’s disease. Biology (Basel). 2023;12(2). doi: 10.3390/biology12020157.
17.
YuC, LiCH, ChenS, YooH, QinX, ParkH. Decreased BDNF release in cortical neurons of a knock-in mouse model of Huntington’s disease. Sci Rep. 2018;8(1):16976. doi: 10.1038/s41598-018-34883-w.
GharamiK, XieY, AnJJ, TonegawaS, XuB. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington’s disease phenotypes in mice. J Neurochem. 2008;105(2):369–79. doi: 10.1111/j.1471-4159.2007.05137.x.
20.
XieY, HaydenMR, XuB. BDNF overexpression in the forebrain rescues Huntington’s disease phenotypes in YAC128 mice. J Neurosci. 2010;30(44):14708–18. doi: 10.1523/JNEUROSCI.1637-10.2010.
21.
SimmonsDA, BelichenkoNP, YangT, CondonC, MonbureauM, ShamlooM, et al. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington’s disease. J Neurosci. 2013;33(48):18712–27. doi: 10.1523/JNEUROSCI.1310-13.2013.
22.
Garcia-Diaz BarrigaG, GiraltA, Anglada-HuguetM, Gaja-CapdevilaN, OrlandiJG, SorianoJ, et al. 7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington’s disease mouse model through specific activation of the PLCgamma1 pathway. Hum Mol Genet. 2017;26(16):3144–60. doi: 10.1093/hmg/ddx198.
23.
JiangM, PengQ, LiuX, JinJ, HouZ, ZhangJ, et al. Small molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington’s disease. Hum Mol Genet. 2013;22(12):2462–70. doi: 10.1093/hmg/ddt098.
24.
FreemanAY, SoghomonianJJ, PierceRC. Tyrosine kinase B and C receptors in the neostriatum and nucleus accumbens are co-localized in enkephalin-positive and enkephalin-negative neuronal profiles and their expression is influenced by cocaine. Neuroscience. 2003;117(1):147–56. doi: 10.1016/s0306-4522(02)00802-3.
25.
Gomez-PinedaVG, Torres-CruzFM, Vivar-CortesCI, Hernandez-EcheagarayE. Neurotrophin-3 restores synaptic plasticity in the striatum of a mouse model of Huntington’s disease. CNS Neurosci Ther. 2018;24(4):353–63. doi: 10.1111/cns.12824.
26.
Perez-NavarroE, CanudasA, AkerundP, AlberchJ, ArenasE. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington’s disease. J Neurochem. 2000;75:2190–9.
27.
El OuaamariY, Van den BosJ, WillekensB, CoolsN, WensI. Neurotrophic factors as regenerative therapy for neurodegenerative diseases: Current status, challenges and future perspectives. Int J Mol Sci. 2023;24(4). doi: 10.3390/ijms24043866.
28.
VolinskyN, KholodenkoBN. Complexity of receptor tyrosine kinase signal processing. Cold Spring Harb Perspect Biol. 2013;5(8):a009043. doi: 10.1101/cshperspect.a009043.
29.
YangT, MassaSM, TranKC, SimmonsDA, RajadasJ, ZengAY, et al. A small molecule TrkB/TrkC neurotrophin receptor co-activator with distinctive effects on neuronal survival and process outgrowth. Neuropharmacology. 2016;110(Pt A):343–61. doi: 10.1016/j.neuropharm.2016.06.015.
30.
MangiariniL, SathasivamK, SellerM, CozensB, HarperA, HetheringtonC, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3):493–506.
31.
HickeyMA, KosmalskaA, EnayatiJ, CohenR, ZeitlinS, LevineMS, et al. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington’s disease mice. Neuroscience. 2008;157(1):280–95. doi: 10.1016/j.neuroscience.2008.08.041.
32.
MenalledLB, SisonJD, DragatsisI, ZeitlinS, ChesseletMF. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington’s disease with 140 CAG repeats. J Comp Neurol. 2003;465(1):11–26.
33.
MatsuuraK, KabutoH, MakinoH, OgawaN. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods. 1997;73(1):45–8. doi: 10.1016/s0165-0270(96)02211-x.
34.
SimmonsDA, MehtaRA, LauterbornJC, GallCM, LynchG. Brief ampakine treatments slow the progression of Huntington’s disease phenotypes in R6/2 mice. Neurobiol Dis. 2011;41(2):436–44. doi: 10.1016/j.nbd.2010.10.015.
35.
MetzGA, WhishawIQ. The ladder rung walking task: A scoring system and its practical application. J Vis Exp. 2009(28). doi: 10.3791/1204.
36.
FranklinK, PaxinosG. The mouse brain in stereotaxic coordinates. New York: Elsevier Inc.; 2008.
37.
HuangEJ, ReichardtLF. Trk receptors: Roles in neuronal signal transduction. Annu Rev Biochem. 2003;72:609–42. doi: 10.1146/annurev.biochem.72.121801.161629.
ColinE, RegulierE, PerrinV, DurrA, BriceA, AebischerP, et al. Akt is altered in an animal model of Huntington’s disease and in patients. Eur J Neurosci. 2005;21(6):1478–88. doi: EJN3985 [pii]10.1111/j.1460-9568.2005.03985.x.
40.
SimmonsDA, BelichenkoNP, FordEC, SemaanS, MonbureauM, AiyaswamyS, et al. A small molecule p75NTR ligand normalizes signalling and reduces Huntington’s disease phenotypes in R6/2 and BACHD mice. Hum Mol Genet. 2016;25(22):4920–38. doi: 10.1093/hmg/ddw316.
41.
LaiKO, LiangZ, FeiE, HuangH, IpNY. Cyclin-dependent Kinase 5 (Cdk5)-dependent phosphorylation of p70 ribosomal S6 kinase 1 (S6K) is required for dendritic spine morphogenesis. J Biol Chem. 2015;290(23):14637–46. doi: 10.1074/jbc.M114.627117.
42.
RuvinskyI, MeyuhasO. Ribosomal protein S6 phosphorylation: From protein synthesis to cell size. Trends Biochem Sci. 2006;31(6):342–8. doi: 10.1016/j.tibs.2006.04.003.
43.
DaviesS, TurmaineM, CozensB, DiFigliaM, SharpA, RossC, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90(3):537–48.
44.
DiFigliaM, SappE, ChaseK, DaviesS, BatesG, VonsattelJ, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277(5334):1990–3.
PouladiMA, MortonAJ, HaydenMR. Choosing an animal model for the study of Huntington’s disease. Nat Rev Neurosci. 2013;14(10):708–21. doi: 10.1038/nrn3570.
47.
van DellenA, WelchJ, DixonRM, CorderyP, YorkD, StylesP, et al. N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington’s disease mice. Neuroreport. 2000;11(17):3751–7.
48.
BibbJA, YanZ, SvenningssonP, SnyderGL, PieriboneVA, HoriuchiA, et al. Severe deficiencies in dopamine signaling in presymptomatic Huntington’s disease mice. Proc Natl Acad Sci U S A. 2000;97(12):6809–14.
49.
Torres-PerazaJ, PezziS, CanalsJM, GavaldaN, Garcia-MartinezJM, Perez-NavarroE, et al. Mice heterozygous for neurotrophin-3 display enhanced vulnerability to excitotoxicity in the striatum through increased expression of N-methyl-D-aspartate receptors. Neuroscience. 2007;144(2):462–71. doi: 10.1016/j.neuroscience.2006.09.038.
50.
BerghuisP, DobszayMB, SousaKM, SchulteG, MagerPP, HartigW, et al. Brain-derived neurotrophic factor controls functional differentiation and microcircuit formation of selectively isolated fast-spiking GABAergic interneurons. Eur J Neurosci. 2004;20(5):1290–306. doi: 10.1111/j.1460-9568.2004.03561.x.
51.
CicchettiF, PrensaL, WuY, ParentA. Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington’s disease. Brain Res Brain Res Rev. 2000;34(1-2):80–101. doi: 10.1016/s0165-0173(00)00039-4.
52.
EtoR, AbeM, KimotoH, ImaokaE, KatoH, KasaharaJ, et al. Alterations of interneurons in the striatum and frontal cortex of mice during postnatal development. Int J Dev Neurosci. 2010;28(5):359–70. doi: 10.1016/j.ijdevneu.2010.04.004.
53.
GrosseG, DjalaliS, DengDR, HoltjeM, HinzB, SchwartzkopffK, et al. Area-specific effects of brain-derived neurotrophic factor (BDNF) genetic ablation on various neuronal subtypes of the mouse brain. Brain Res Dev Brain Res. 2005;156(2):111–26. doi: 10.1016/j.devbrainres.2004.12.012.
BennettBD, BolamJP. Synaptic input and output of parvalbumin-immunoreactive neurons in the neostriatum of the rat. Neuroscience. 1994;62(3):707–19. doi: 10.1016/0306-4522(94)90471-5.
SappE, KegelK, AroninN, HashikawaT, UchiyamaY, TohyamaK, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol. 2001;60(2):161–72.
59.
SimmonsDA, CasaleM, AlconB, PhamN, NarayanN, LynchG. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington’s disease. Glia. 2007;55(10):1074–84.
60.
ItoD, ImaiY, OhsawaK, NakajimaK, FukuuchiY, KohsakaS. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res. 1998;57(1):1–9.
61.
RidleyA, PatersonH, JohnstonC, DiekmannD, HallA. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. 1992;70(3):401–10.
62.
Torres-PlatasSG, ComeauS, RachalskiA, BoGD, CruceanuC, TureckiG, et al. Morphometric characterization of microglial phenotypes in human cerebral cortex. J Neuroinflammation. 2014;11:12. doi: 10.1186/1742-2094-11-12.
63.
WackerJL, HuangSY, SteeleAD, AronR, LotzGP, NguyenQ, et al. Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington’s disease. J Neurosci. 2009;29(28):9104–14. doi: 10.1523/JNEUROSCI.2250-09.2009.
64.
SpiresTL, GroteHE, GarryS, CorderyPM, Van DellenA, BlakemoreC, et al. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington’s disease transgenic mice. Eur J Neurosci. 2004;19(10):2799–807.
65.
FerranteRJ, KowallNW, RichardsonEPJr.. Proliferative and degenerative changes in striatal spiny neurons in Huntington’s disease: A combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci. 1991;11(12):3877–87.
66.
GravelandG, WilliamsR, DiFigliaM. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington’s disease. Science. 1985;227(4688):770–3.
67.
ParkH, PooMM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci. 2013;14(1):7–23. doi: 10.1038/nrn3379.
68.
WangL, ChangX, SheL, XuD, HuangW, PooMM. Autocrine action of BDNF on dendrite development of adult-born hippocampal neurons. J Neurosci. 2015;35(22):8384–93. doi: 10.1523/JNEUROSCI.4682-14.2015.
69.
HickeyMA, GallantK, GrossGG, LevineMS, ChesseletMF. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis. 2005;20(1):1–11. doi: 10.1016/j.nbd.2005.01.024.
70.
StackEC, KubilusJK, SmithK, CormierK, Del SignoreSJ, GuelinE, et al. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington’s disease transgenic mice. J Comp Neurol. 2005;490(4):354–70. doi: 10.1002/cne.20680.
71.
FileSE, MahalA, MangiariniL, BatesGP. Striking changes in anxiety in Huntington’s disease transgenic mice. Brain Res. 1998;805(1-2):234–40. doi: 10.1016/s0006-8993(98)00736-7.
72.
LernerRP, Trejo Martinez LdelC, ZhuC, ChesseletMF, HickeyMA. Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington’s disease. Brain Res Bull. 2012;87(6):571–8. doi: 10.1016/j.brainresbull.2012.01.012.
73.
RisingAC, XuJ, CarlsonA, NapoliVV, Denovan-WrightEM, MandelRJ. Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington’s disease with 140 CAG repeats. Exp Neurol. 2011;228(2):173–82. doi: 10.1016/j.expneurol.2010.12.017.
74.
SimmonsDA, RexCS, PalmerL, PandyarajanV, FedulovV, GallCM, et al. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington’s disease knockin mice. Proc Natl Acad Sci U S A. 2009;106(12):4906–11. doi: 10.1073/pnas.0811228106.
75.
GuziorN, WieckowskaA, PanekD, MalawskaB. Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer’s disease. Curr Med Chem. 2015;22(3):373–404. doi: 10.2174/0929867321666141106122628.
76.
BaydyukM, XuB. BDNF signaling and survival of striatal neurons. Front Cell Neurosci. 2014;8:254. doi: 10.3389/fncel.2014.00254.
77.
GalvanL, AndreVM, WangEA, CepedaC, LevineMS. Functional differences between direct and indirect striatal output pathways in Huntington’s disease. J Huntingtons Dis. 2012;1(1):17–25. doi: 10.3233/JHD-2012-120009.
78.
BregmanBS, McAteeM, DaiHN, KuhnPL. Neurotrophic factors increase axonal growth after spinal cord injury and transplantation in the adult rat. Exp Neurol. 1997;148(2):475–94. doi: 10.1006/exnr.1997.6705.
79.
Torres-CruzFM, MendozaE, Vivar-CortesIC, Garcia-SierraF, Hernandez-EcheagarayE. Do BDNF and NT-4/5 exert synergistic or occlusive effects on corticostriatal transmission in a male mouse model of Huntington’s disease?J Neurosci Res. 2019;97(12):1665–77. doi: 10.1002/jnr.24507.
HumbertS, BrysonEA, CordelieresFP, ConnorsNC, DattaSR, FinkbeinerS, et al. The IGF-1/Akt pathway is neuroprotective in Huntington’s disease and involves Huntingtin phosphorylation by Akt. Dev Cell. 2002;2(6):831–7. doi: 10.1016/s1534-5807(02)00188-0.
82.
RangoneH, PardoR, ColinE, GiraultJA, SaudouF, HumbertS. Phosphorylation of arfaptin 2 at Ser260 by Akt Inhibits PolyQ-huntingtin-induced toxicity by rescuing proteasome impairment. J Biol Chem. 2202;280(23):1–8. doi: 10.1074/jbc.M407528200.
83.
RouxPP, ShahbazianD, VuH, HolzMK, CohenMS, TauntonJ, et al. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem. 2007;282(19):14056–64. doi: 10.1074/jbc.M700906200.
84.
NakaoN, OdinP, LindvallO, BrundinP. Differential trophic effects of basic fibroblast growth factor, insulin-like growth factor-1, and neurotrophin-3 on striatal neurons in culture. Exp Neurol. 1996;138(1):144–57. doi: 10.1006/exnr.1996.0053.
85.
CanalsJM, PinedaJR, Torres-PerazaJF, BoschM, Martin-IbanezR, MunozMT, et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington’s disease. J Neurosci. 2004;24(35):7727–39. doi: 10.1523/JNEUROSCI.1197-04.2004.
86.
BogushA, PedriniS, Pelta-HellerJ, ChanT, YangQ, MaoZ, et al. AKT and CDK5/p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro. J Biol Chem. 2007;282(10):7352–9. doi: 10.1074/jbc.M606508200.
87.
StroppoloA, GuineaB, TianC, SommerJ, EhrlichME. Role of phosphatidylinositide 3-kinase in brain-derived neurotrophic factor-induced DARPP-32 expression in medium size spiny neurons in vitro. J Neurochem. 2001;79(5):1027–32.
88.
KosinskiCM, ChaJH, YoungAB, MangiariniL, BatesG, SchieferJ, et al. Intranuclear inclusions in subtypes of striatal neurons in Huntington’s disease transgenic mice. Neuroreport. 1999;10(18):3891–6.
89.
GiampaC, MiddeiS, PatassiniS, BorrecaA, MarulloF, LaurentiD, et al. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington’s disease. Eur J Neurosci. 2009;29(5):902–10. doi: 10.1111/j.1460-9568.2009.06649.x.
90.
PhamAQ, DoreK. Novel approaches to increase synaptic resilience as potential treatments for Alzheimer’s disease. Semin Cell Dev Biol. 2023;139:84–92. doi: 10.1016/j.semcdb.2022.03.032.
91.
BarronJC, HurleyEP, ParsonsMP. Huntingtin and the synapse. Front Cell Neurosci. 2021;15:689332. doi: 10.3389/fncel.2021.689332.
92.
TyebjiS, HannanAJ. Synaptopathic mechanisms of neurodegeneration and dementia: Insights from Huntington’s disease. Prog Neurobiol. 2017;153:18–45. doi: 10.1016/j.pneurobio.2017.03.008.
93.
Smith-DijakAI, SepersMD, RaymondLA. Alterations in synaptic function and plasticity in Huntington disease. J Neurochem. 2019;150(4):346–65. doi: 10.1111/jnc.14723.
WennagelD, BrazBY, CapizziM, BarnatM, HumbertS. Huntingtin coordinates dendritic spine morphology and function through cofilin-mediated control of the actin cytoskeleton. Cell Rep. 2022;40(9):111261. doi: 10.1016/j.celrep.2022.111261.
96.
MilnerwoodAJ, CummingsDM, DalleracGM, BrownJY, VatsavayaiSC, HirstMC, et al. Early development of aberrant synaptic plasticity in a mouse model of Huntington’s disease. Hum Mol Genet. 2006;15(10):1690–703.
OrthM, SchipplingS, SchneiderSA, BhatiaKP, TalelliP, TabriziSJ, et al. Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease. J Neurol Neurosurg Psychiatry. 2010;81(3):267–70. doi: 10.1136/jnnp.2009.171926.
99.
Ammendrup-JohnsenI, NaitoY, CraigAM, TakahashiH. Neurotrophin-3 enhances the synaptic organizing function of TrkC-protein tyrosine phosphatase sigma in rat hippocampal neurons. J Neurosci. 1242;35(36):5–31. doi: 10.1523/JNEUROSCI.1330-15.2015.
100.
DrakeCT, MilnerTA, PattersonSL. Ultrastructural localization of full-length trkB immunoreactivity in rat hippocampus suggests multiple roles in modulating activity-dependent synaptic plasticity. J Neurosci. 1999;19(18):8009–26.
101.
WuK, XuJL, SuenPC, LevineE, HuangYY, MountHT, et al. Functional trkB neurotrophin receptors are intrinsic components of the adult brain postsynaptic density. Brain Res Mol Brain Res. 1996;43(1-2):286–90.
102.
YoshiiA, Constantine-PatonM. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol. 2010;70(5):304–22. doi: 10.1002/dneu.20765.
103.
LynchG, KramarEA, RexCS, JiaY, ChappasD, GallCM, et al. Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington’s disease. J Neurosci. 2007;27(16):4424–34.
104.
JiaY, GallCM, LynchG. Presynaptic BDNF promotes postsynaptic long-term potentiation in the dorsal striatum. J Neurosci. 2010;30(43):14440–5. doi: 10.1523/JNEUROSCI.3310-10.2010.
105.
BaquetZC, GorskiJA, JonesKR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci. 2004;24(17):4250–8.
106.
KangHJ, SchumanEM. Neurotrophin-induced modulation of synaptic transmission in the adult hippocampus. J Physiol Paris. 1995;89(1):11–22.
107.
HanKA, WooD, KimS, ChoiiG, JeonS, WonSY, et al. Neurotrophin-3 regulates synapse development by modulating TrkC-PTPsigma synaptic adhesion and intracellular signaling pathways. J Neurosci. 2016;36(17):4816–31. doi: 10.1523/JNEUROSCI.4024-15.2016.
108.
Ramos-LangurenLE, EscobarML. Plasticity and metaplasticity of adult rat hippocampal mossy fibers induced by neurotrophin-3. Eur J Neurosci. 2013;37(8):1248–59. doi: 10.1111/ejn.12141.
109.
ChenJY, WangEA, CepedaC, LevineMS. Dopamine imbalance in Huntington’s disease: A mechanism for the lack of behavioral flexibility. Front Neurosci. 2013;7:114. doi: 10.3389/fnins.2013.00114.
GharaibehA, MaitiP, CulverR, HeilemanS, SrinageshwarB, StoryD, et al. Solid lipid curcumin particles protect medium spiny neuronal morphology, and reduce learning and memory deficits in the YAC128 mouse model of Huntington’s disease. Int J Mol Sci. 2020;21(24). doi: 10.3390/ijms21249542.
112.
ToddD, GowersI, DowlerSJ, WallMD, McAllisterG, FischerDF, et al. A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington’s disease. PLoS One. 2014;9(2):e87923. doi: 10.1371/journal.pone.0087923.
113.
GonzalezS, McHughTLM, YangT, SyrianiW, MassaSM, LongoFM, et al. Small molecule modulation of TrkB and TrkC neurotrophin receptors prevents cholinergic neuron atrophy in an Alzheimer’s disease mouse model at an advanced pathological stage. Neurobiol Dis. 2022;162:105563. doi: 10.1016/j.nbd.2021.105563.
114.
SimiA, IbanezCF. Assembly and activation of neurotrophic factor receptor complexes. Dev Neurobiol. 2010;70(5):323–31. doi: 10.1002/dneu.20773.
115.
Hernandez-EcheagarayE. The role of the TrkB-T1 receptor in the neurotrophin-4/5 antagonism of brain-derived neurotrophic factor on corticostriatal synaptic transmission. Neural Regen Res. 2020;15(11):1973–6. doi: 10.4103/1673-5374.282224.
116.
ShenJ, SunD, ShaoJ, ChenY, PangK, GuoW, et al. Extracellular juxtamembrane motif critical for TrkB preformed dimer and activation. Cells. 2019;8(8). doi: 10.3390/cells8080932.
117.
LongoFM, MassaSM. Small-molecule modulation of neurotrophin receptors: A strategy for the treatment of neurological disease. Nat Rev Drug Discov. 2013;12(7):507–25.
